Virtual Library
Start Your Search
Voc Tai Dang
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-16 - Characteristics of Stage III Lung Cancer Patients in the Period 2014-2016 in Vietnam (Now Available) (ID 1231)
08:00 - 18:00 | Presenting Author(s): Voc Tai Dang
- Abstract
Background
Despite lung cancer is the leading cause of cancer-related mortality around the world, data and impact on health systems related to characteristics of the diseases is not fully understood in developing countries. The study aims to describe and evaluate the characteristics stage III lung cancer patients in Vietnam.
Method
Medical records of patient with diagnosis of stage III lung cancer hospitalized in the period 2012-2015 in the National Cancer Hospital (Vietnam) were retrospectively analyzed. Patients were followed up about the survival information in April 2019 to identify overall survival (OS) rates. We compared the efficacy of treatments between 2 patient groups: surgery and/or radio-chemotherapy (group 1) and radiotherapy only or chemotherapy only or supportive care only (group 2).
Result
From a total of 5220 lung cancer patient hospitalized in the National Cancer Hospital over 3-year period, we reviewed 600 original medical records, of which 70 stage III lung cancer patients having valid survival information were identified (11.7%). We found 60 patients with death outcome (85.7%) and median OS and its 95% confidence interval were 9.80 [5.39, 19.70]. Patients were mainly men (54, 77.1%) with mean age (SD) was 65.96 (8.62). We found 14 patients with surgery and/or radio-chemotherapy in group 1 (4 surgery and 10 radio-chemotherapy). In group 2, 34 patients were treated with chemotherapy or radiotherapy alone, and 22 patients were provided supportive care only. The estimated 1-year, 3-year and 5-year survival probabilities were 40.7 (30.6 - 54.1) %, 15.5 (08.8 - 27.1)% and 10.3 (04.64 - 22.9)% correspondingly. We estimated 3-year survival probability of patients in group 1 was 34.3 (16.24 - 72.4 %) was higher than group 2 which was 10.6 (4.89 - 23.2)% (p=0.055).
Conclusion
Our results showed a benefit of surgery and/or radio-chemotherapy treatment on stage III lung cancer patients in Vietnam. Further research is required.
-
+
EP1.03 - Biology (ID 193)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Biology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.03-32 - Prevalence of EGFR and ALK Mutations in Non Small Cell Lung Cancer in Viet Nam National Cancer Hospital (Now Available) (ID 979)
08:00 - 18:00 | Presenting Author(s): Voc Tai Dang
- Abstract
Background
A significant percentage of non small cell lung cancer (NSCLC) have driver mutations. Epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing NSCLC. To date, there has been no assessment of the prevalence of these mutations in NSCLC in Viet Nam National Cancer Hospital. The prospective study of formalin fixed paraffin embedded (FFPE) tissues from patients diagnosed with NSCLC was performed to assess the prevalence of EGFR and ALK mutations in NSCLC in Viet Nam National Cancer Hospital.
Method
Patients with NSCLC in Viet Nam National Cancer Hospital were prospectively enrolled. FFPE tissue samples were tested for EGFR mutation by PCR and for EML4-ALK translocation by fluorescence in situ hybridization (FISH)
Result
A total of 103 patients were enrolled, 78 (76.7%) males and 25 females (23.3%), with a mean age of 57.7 years. Adenocarcinoma and Squamous cell carcinoma rate were 89.3% and 10.7%, respectively. EGFR testing of 103 patients (100%) demonstrated the wild type in 76 (73.8%) and mutated forms in 27 (26.2%). Some 74.0% of EGFR positive patients were non-smokers and 44.4% were females. Regarding the EML4-ALK translocation, testing in 103 cases (100%) gave positive results in only 11 (10.7%). Among 11 patients with EML4-ALK translocation, 6 patients (54.5 %) were females and 6 patients (54.5 %) were smokers. Moreover, only two squamous cell carcinoma patients had positive EGFR mutation and only one patient had concurrent EGFR mutation and ALK rearrangement
Conclusion
In this sudy investigating the prevalence of EGFR and ALK mutations in non small cell lung cancer in Vietnam National Cancer Hospital, 26.2% had EGFR mutation and 10.7% had ALK translocation mutations, as compared to 35% and 6.1%, respectively, in Asian
